Summary & Overview
HCPCS Level II J0150: Adenosine injection, 6 mg therapeutic use
HCPCS Level II code J0150 denotes a 6 mg therapeutic injection of adenosine, a rapid-acting antiarrhythmic used primarily to manage certain supraventricular tachycardias. Nationally, accurate reporting of this HCPCS Level II code supports clinical documentation, appropriate billing for acute cardiac interventions, and clear differentiation from related adenosine phosphate products reported with a9270.
Key payers referenced in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of adenosine, the typical sites of service where the injection is administered, and the implications of correct HCPCS Level II coding for claims processing. The publication also outlines common billing considerations and related code distinctions important for consistent national reporting.
This resource provides benchmarks and policy-relevant guidance on code usage, clarifies when J0150 applies versus other supply or drug codes, and highlights documentation elements that payers commonly review. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J0150 describes an injection of adenosine for therapeutic use, 6 mg. The code specifies that it is not to be used to report any adenosine phosphate compounds, which should instead be reported with a9270.
Service type: Therapeutic cardiac medication administration — administration of a rapid-acting antiarrhythmic agent used in certain supraventricular tachycardias.
Typical site of service: Hospital or clinic setting, commonly administered in emergency departments, inpatient units, or monitored procedural areas where cardiac monitoring and immediate clinical response are available.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an emergency department or cardiology clinic with symptomatic supraventricular tachycardia (SVT) characterized by sudden-onset palpitations, lightheadedness, and a narrow-complex tachycardia on ECG. After assessment and failed vagal maneuvers, the treating physician orders intravenous adenosine for diagnostic and therapeutic termination of re-entrant SVT.
The clinical workflow: the patient is placed on continuous cardiac monitoring with IV access established. Baseline vital signs and a 12-lead ECG are documented. A rapid IV bolus of J0150 (adenosine, 6 mg) is prepared at the bedside, often followed by a rapid saline push and immediate ECG monitoring to capture transient AV block or rhythm conversion. If the initial 6 mg bolus does not terminate the arrhythmia, subsequent escalating boluses (typically 12 mg) are administered per clinical protocol; however, additional adenosine doses beyond the first 6 mg are reported per facility policy and payer guidance. Observation continues until rhythm normalizes and hemodynamics are stable; typical sites of service include the emergency department, inpatient hospital unit, or observation unit. Common patient considerations include asthma/COPD history and concomitant medications that may potentiate bradyarrhythmia.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure |